中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 5
May  2011
Turn off MathJax
Article Contents

Prognostic factors in the prediction of survival following TIPS for cirrhosis and refractory ascites

  • Published Date: 2011-05-20
  • Objective To analyse the prognostic factors of survival in patients with cirrhosis and refractory ascites treated with TIPS.Methods From January 2003 to February 2009, a cohort of 25 hospitalized patients with cirrhosis and refractory ascites treated with TIPS were retrospectively studied, and data were abstracted including baseline characteristics of patients and all biochemical variables within 7 days after being referred to our hospital.The major endpoints was death.Cox proportional hazards method was used to assess the prognostic value of the variables found to be significant in univariate analysis.For those variables, cut-off values according to ROC curves, were determined so as to get a sensitivity over 80%.Results The median time of follow up was 18 months (range 1-40 months) , 6 patients died and no liver transplantation was performed within the first year of follow up.The cumulative 3-month and 1-year survival rate were 84% and 67% respectively.Using multivariate analysis, only serum bilirubin and creatinine levels were independently associated with 1-year survival.According to ROC analysis, we selected the cut-off values of 46 μmol//L for serum bilirubin level (sensitivity = 86%, specificity = 35%) and 132 μmol//L for serum creatinine level (sensitivity = 83%, specificity = 33%) .In addition, Kaplan-Meier survival analysis demonstrated that the 1-year cumulative survival in patients with serum bilirubin level <46 μmol/L was 92% as compared to 37% in patients with serum bilirubin level ≥46 μmol/L (P<0.001) .The 1-year cumulative survival of patients with creatinine <132 μmol/L was 89% versus 43% for ≥132 μmol/L (P<0.05) .Conclusion A serum bilirubin level above 46 μmol/L and creatinine above 132 μmol/L are prognostic factors in patients with cirrhosis and refractory ascites treated with TIPS.This simple score could be used at bedside to help choosing the best therapeutic options.

     

  • loading
  • [1]Narahara Y, Kanazawa H, Fukuda T, et al.Transjugular intrahepaticportosystemic shunt versus paracentesis plus albumin in patientswith refractory ascites who have good hepatic and renal function:aprospective randomized trial[J].J Gastroenterol, 2011, 46 (1) :78-85.
    [2]Lebrec D, Giuily N, Hadengue A, et al.Transjugularintrahepaticportosystemic shunt:comparison with paracentesisin patients with cirrhosis and refractory ascites:a randomizedtrial[J].J Hepatol, 1996, 25 (2) :135-144.
    [3]R?ssle M, Ochs A, Gulberg V, et al.A comparison of paracentesisand transjugular intrahepatic portosystemic shunting in patientswith ascites[J].N Engl J Med, 2000, 342 (23) :1701-1707.
    [4]Ginès P, Uriz J, Calahorra B, et al.Transjugular intrahepatic portosystemicshunting versus paracentesis plus albumin for refractory ascites incirrhosis[J].Gastroenterology, 2002, 123 (6) :1839-1847.
    [5]Sanyal AJ, Genning C, Reddy KR, et al.The NorthAmerican Study for the treatment of refractory ascites[J].Gastroenterology, 2003, 124 (3) :634-641.
    [6]Salerno F, Merli M, Riggio O, et al.Randomized controlledstudy of TIPS versus paracentesis plus albumin in cirrhosis withsevere ascites[J].Hepatology, 2004, 40 (3) :629-635.
    [7]Guy J, Somsouk MA, Biggins SW, et al.New model for endstage liver disease improves prognostic capability aftertransjugular intrahepatic portosystemic shunt[J].ClinGastroenterol Hepatol, 2009, 7 (11) :1236-1240.
    [8]Moore KP, Wong F, Gines P, et al.The management of ascites incirrhosis:report on the consensus conference of the InternationalAscites Club[J].Hepatology, 2003, 38 (1) :258-266.
    [9]Rajan DK, Haskal ZJ, Clark TW.Serum bilirubin and early mortalityafter transjugular intrahepatic portosystemic shunts:results of amultivariate analysis[J].J Vasc Interv Radiol, 2002, 13 (2) :155-161.
    [10]Chalasani N, Clark W, Martin L, et al.Determinants of mortality inpatients with advanced cirrhosis after transjugular intrahepaticportosystemic shunting[J].Gastroenterology, 2000, 118 (1) :138-144.
    [11]Bureau C, Métivier S, D'Amico M, et al.Serum bilirubin and plateletcount:a simple predictive model for survival in patients with refractoryascites treated by TIPS[J].J Hepatol, 2011.[Epub ahead of print]
    [12]Malinchoc M, Kamath PS, Gordon F, et al.A model to predictpoor survival in patients undergoing transjugular intrahepaticportosystemic shunts[J].Hepatology, 2000, 31 (4) :864-871.
    [13]Nazarian G, Bjarnason H, Dietz CA, et al.Refractory ascites:midterm results of treatment with a transjugular interhepaticportosystemic shunt[J].Radiology, 1997, 205 (1) :173-180.
    [14]Russo MW, Jacques PF, Mauro M, et al.Predictors of mortalityand stenosis after transjugular intrahepatic portosystemicshunt[J].Liver Transpl, 2002, 8 (3) :271-277.
    [15]Lim YS, Larson TS, Benson JT, et al.Serum sodium, renalfunction and survival of patients with end-stage liverdisease[J].J Hepatol, 2010, 52 (4) :523-528.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (4174) PDF downloads(1029) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return